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Background. The rapid scale-up of antiretroviral therapy in resource-limited settings has greatly increased demand for
antiretroviral medicines and raised the importance of good forward planning, especially in the context of the new 2010 WHO
treatment guidelines. Methods. Forecasting of the number of people receiving antiretroviral therapy from 2010 to 2012 was
produced using three approaches: linear projection, country-set targets, and a restricted scenario. Two additional scenarios were
then used to project the demand for various antiretroviral medicines under a fast and slower phase-out of stavudine. Results.W e
projected that between 7.1 million and 8.4 million people would be receiving ART by the end of 2012. Of these, 6.6% will be
on second-line therapy. High variation in forecast includes reductions in the demand for d4T and d4T increases in the demand
for tenofovir, emtricitabine followed by efavirenz, ritonavir, zidovudine and lopinavir; lamivudine, atazanavir, and nevirapine.
Conclusion. Despite the global economic crisis and in response to the revised treatment guidelines, our model forecasts an
increasing and shifting demand for antiretrovirals in resource-limited settings not only to provide treatment to new patients,
but also to those switching to less toxic regimens.
1.Introduction
Inthepastﬁveyears,low-andmiddle-incomecountrieshave
aggressively scaled up HIV treatment. By the end of 2009,
more than 5.2 million people were receiving antiretroviral
therapy [1]. This represented an increase of more than 1.2
million people from the end of 2008 and a 13-fold expansion
over the previous six years. This rapid scale-up has greatly
increased the demand on antiretroviral medicines and raised
the importance of good forward planning.
The new forecasts presented here update previous esti-
mates [2–4] by adding updated information on the number
of people receiving antiretroviral therapy and data from
the annual WHO AIDS Medicines and Diagnostics Service
(AMDS) survey on the use of antiretrovirals [5–7]. Two
major elements taken into account for developing updated
forecasts were the ﬁnancial crisis and the progressive imple-
mentation of the new WHO antiretroviral therapy (ART)
recommendations published in 2010 [8].
Under the revised WHO guidelines, an estimated 14.6
million (13.4–15.4 million) people in low- and middle-
income countries will be eligible for ART, a 45% increase
from the 10.1 million (9.0–11.1 million) people in need
of ART under the previous guidelines. While the predicted
expansion of HIV treatment is well below 14.6 million, the
ﬁgures in this paper are not a statement about what should
be or will be accomplished in 2012. Rather, these estimates
indicate what is likely to be accomplished in the absence
of meaningful changes in the conditions driving treatment
scale-up.2 AIDS Research and Treatment
2. Methods
Estimates of the number of people receiving antiretro-
viral therapy were forecast from 2010 to 2012 using
three approaches: linear projection, country-set targets and
restricted scenario. To forecast the demand for antiretroviral
medicines, two additional scenarios were included: a fast and
slower phase-out of stavudine, with a baseline consumption
takenfromthe2009WHOsurveyonantiretroviraluse.Once
the number of patients on treatment was estimated, these
numbers were translated into volumes of active pharmaceu-
tical ingredients.
2.1. Multicountry Survey on ARV Use. In March 2009, the
WHO Department of HIV and AIDS conducted the third
annualsurveytoassessantiretroviraluseinlow-andmiddle-
income countries. A standard questionnaire was sent to the
43 countries with the highest number of people receiving
antiretroviral therapy as of December 2008. National AIDS
programmes of 39 countries responded and completed the
questionnaires; these were collected by the WHO countries
and regional oﬃces and forwarded to the WHO AMDS team
in Geneva.
2.2. Forecasting the Number of Patients Receiving Treatment
2.2.1. Choice of Forecasting Approach. Three forecast
approaches were considered: linear projection, country-set
targets, and restricted scenario. The linear projection is
based on projections of historical trends of the number of
people receiving antiretroviral therapy by country, from the
data reported between December 2006 and December 2008
for each country. This approach is a linear extrapolation
using a regression line through the last three data points to
determinetheaverageannualincrease.Thisincreaseisadded
to the estimated number of people receiving antiretroviral
therapy as of December 2008. This approach has the
advantage of being grounded in actual country-observed
data and is easy to implement and understand. Since it
could result in a projection greater than total estimated
need, all projections were capped at the level established
for the country-set target scenario. Recent growth has been
approximately linear, so this approach represents the best
projection, assuming that past trends continue.
The second scenario was adjusted using targets set by
countries for the number of people that they expect to reach
with antiretroviral therapy by 2012. These targets take into
account the realities in each country and their goals for
increasing coverage. During a consultation at the WHO in
GenevainOctober2009,ﬁvecountriesreportedtheirtargets:
India, Kenya, South Africa, Thailand, and Zambia. Together,
these countries account for approximately 40% of people
receiving antiretroviral therapy. In the country-set target
projection, it is assumed that the total number of people
receiving antiretroviral therapy will grow at the same rate as
the projected number for the ﬁve countries.
The two scenarios using linear projection and country
targets may be over-optimistic if the economic crisis results
in slower growth in international and national ﬁnancing
of antiretroviral therapy programmes [9–11]. A restricted
scenario was therefore created to consider this possibility.
Undertherestrictedscenario,thenumberofpeoplereceiving
antiretroviraltherapygrowsatonly75%oftheannualrateof
the target scenario.
The three methods described above were applied to each
of the 154 countries in the analysis and the results were
aggregated to regional and interregional totals.
This exercise deﬁned the number of people receiving
antiretroviral therapy as the number of people receiving
antiretroviraltherapyattheendofagivenyear.Thisincludes
people who started antiretroviral therapy in that year, as
well as those who started in previous years and remained on
treatment.
2.2.2. Retention Assumptions. The proportion of people
receiving antiretroviral therapy in one year who continue
on antiretroviral therapy through the same programme in
a subsequent year is called the retention rate. A number
of countries estimate retention rates from their programme
data. Published data from the Towards Universal Access 2009
report have been consolidated into ﬁrst year and subsequent
years, resulting in a 79.5% overall retention rate for the ﬁrst
year and 95.8% for subsequent years [5].
2.2.3. First- and Second-Line Antiretroviral Therapy. The
current proportion of people receiving second-line therapy
was extracted from the 2009 WHO survey on antiretroviral
use. The number of people receiving ﬁrst-line antiretroviral
therapy in any year is projected as the number of people
initiatingantiretroviraltherapyinthatyearplusthosepeople
receiving ﬁrst-line therapy in the previous year who survive
to this year and do not switch to second-line therapy. For
countries without information on the number of people
receiving second-line therapy, a regional average from the
survey was applied: 2.8% for sub-Saharan Africa; 8.2% for
Central America and the Caribbean; 9.1% for Eastern and
Central Europe; 30% for Latin America; 0.2% for South-East
Asia; 2.0% for Western Paciﬁc.
2.2.4. Rate of Switching from First- to Second-Line Antiretro-
viral Therapy. Data from a systematic review of monitoring
strategies,treatmentfailure,andattritionrates,conductedby
WHO in collaboration with the Australian National Centre
in HIV Epidemiology and Clinical Research, were used to
estimate the regional failure rates [12]. The review showed
that when viral load monitoring is used, a failure rate of
6% is detected and that when the CD4 count is used there
is a 1.9% detected failure rate. Data from the review were
usedtoestimatefailureratesforAfrica(2.6%),LatinAmerica
(2.6%), and Asia (1.1%). For countries in all other regions,
the average of 1.9% was used. For Latin American countries
where viral load is used routinely, including Argentina,
Brazil, Mexico, and Venezuela, the 6% rate from the meta-
analysis was used.
2.3. Forecasting Demand for Antiretroviral Medicines. One of
the expected impacts of the new WHO recommendations onAIDS Research and Treatment 3
the use of antiretroviral drugs in low- and middle-income
countries will be a progressive phasing out of stavudine and
an increase in ﬁrst-line regimens based on zidovudine and
tenofovir [8]. The antiretroviral demand forecasts presented
are based on two scenarios, which consider either a fast
or slow phase-out of stavudine. The two scenarios were
developed for both ﬁrst- and second-line regimens, and
the population was divided into two categories within each
scenario: people already receiving antiretroviral therapy and
people initiating antiretroviral therapy, for whom the new
recommendations apply diﬀerently. The baseline is taken
from the 2009 WHO AMDS survey on antiretroviral use.
3. Results
3.1. Use of Antiretroviral Therapy in Low- and Middle-Income
Countries as of December 2008. Thirty-nine national AIDS
programmes responded to the survey, representing a total
of 3.4 million people receiving antiretroviral therapy, or
about 85% of the estimated 4.0 million people receiving
antiretroviral therapy in resource-limited countries as of
December 2008. In these 39 countries, 93% of the people
receiving antiretroviral therapy were adults (3.2 million
adults) and 7% were children (252000 children).
An exploratory data analysis conﬁrmed that the pattern
of use of ﬁrst- and second-line regimens was similar among
the 37 countries that scaled up treatment programmes
after the publication of WHO’s public health approach
to antiretroviral therapy in 2002 [13]. However, in Brazil
and Mexico, where the expansion of treatment programmes
started earlier, the pattern of antiretroviral use was signiﬁ-
cantlydiﬀerent,particularlyforthelevelofuseofsecond-line
regimens. For this reason, data from Brazil and Mexico were
analysed separately from data from other programmes that
have scaled up more recently and are presented separately.
Figure 1 shows the composition and distribution of the
ﬁrst- and second-line regimens most commonly used in
the 37 low- and middle-income countries. In antiretroviral
treatment programmes, the vast majority of adults (98%)
were receiving ﬁrst-line regimens and 2% of patients were
receiving second-line regimens. A vast majority (99%) of
people on ﬁrst-line ART, and 87% of those on second-line
ART, were receiving regimens recommended by the WHO
[14]. More than half of the patients on ﬁrst-line regimens
(62%) were receiving stavudine and 56% were receiving
nevirapine as the nonnucleoside component. Among the 2%
of patients receiving second-line regimens, a majority (55%)
were on a regimen containing zidovudine and 43% were on
one containing tenofovir. Lopinavir boosted with low-dose
ritonavir (LPV/r) was the predominant protease inhibitor,
received by 95% of adults. A vast majority of children (97%)
were receiving ﬁrst-line regimens (237000 children), with
an almost equal distribution between regimens containing
stavudine and zidovudine (49% and 47%, resp.). Brazil and
Mexico reported frequent use of second-line regimens in
adults (20% and 13%, resp.) and very low use of stavudine
and nevirapine in ﬁrst-line regimens. A high proportion of
children in Brazil and Mexico were receiving second-line
therapy (40% and 13%, resp.).
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Figure 1: First- and second-line antiretroviral regimens received by
adults in 37 low- and middle-income countries (n = 2870000 and
n = 67,500), December 2008.
3.2. Antiretroviral Market Trends in 17 Countries from 2006
to 2008. An analysis of 17 countries (Burkina Faso, Burundi,
Cambodia, Cameroon, Cˆ ote d’Ivoire, Ethiopia, India, Kenya,
Lesotho, Namibia, Nigeria, Rwanda, Swaziland, the United
RepublicofTanzania,Uganda,Zambia,andZimbabwe.)that
responded to all three rounds of the WHO survey on ARV
use (2006–2008) showed the antiretroviral market trends
over the three-year period [5]. The analysis conﬁrmed that
the proportion of adults receiving second-line regimens in
antiretroviral therapy programmes remains low with 2.3%
in 2008 (3.5% in 2007 and 2% in 2006). There was a net
increase in tenofovir use in 2008, with 9% and 56% of adults4 AIDS Research and Treatment
receiving tenofovir-based regimens on ﬁrst and second-line
respectively. (1.5% for ﬁrst line and 32% for second line in
2007, and <1% and 11% in 2006). The analysis also showed
a slow decrease in stavudine use, with 57% of adults on
ﬁrst-line regimens receiving stavudine in the 17 countries in
2008 (68% in 2007 and 67% in 2006) and an increase in
zidovudine use, with 35% of adults on ﬁrst-line regimens
receiving zidovudine in 2008 (26% in 2007 and 29% in
2006).
3.3. Evolution in National Antiretroviral Therapy Guidelines.
The survey showed that WHO 2006 treatment recom-
mendations have largely been adopted and implemented
by national HIV programmes, despite a few people still
receiving treatment regimens that are not in line with WHO
guidelines (such as second-line regimens without a protease
inhibitor backbone) [14]. There is a constant evolution in
national treatment guidelines; half the countries were in the
process of revising adult (16 countries) and paediatric (19
countries) protocols at the time of the survey. The most
frequently planned changes in adult guidelines were the
introduction of tenofovir (nine countries), a change from
stavudine as the preferred ﬁrst-line option (seven countries),
an increase in the CD4 threshold for treatment initiation to
below 250cells/mm3 (twocountries) or below 350cells/mm3
(four countries), and the introduction of viral load testing to
monitor treatment (three countries).
3.4. Forecast Numbers of People Receiving Antiretroviral
Therapy in Low- and Middle-Income Countries by 2012.
Figure 2 shows the forecast demand for ART, based on linear
projections, country-set targets, and the restricted scenario,
which projects between 7.1 and 8.4 million people receiving
ART in low- and middle-income countries by the end of
2012. The baseline number of people receiving ART was
4.0 million by the end of 2008 and is projected to increase
to 5.0 million by the end of 2009, 6.0 million by the end
of 2010, 6.9 million by the end of 2011, and 7.9 million
by the end of 2012, according to linear projection. Annual
growth is slightly slower than the growth observed between
2007 and 2008. It is expected that countries with the greatest
number of people receiving antiretroviral therapy would
experience slower enrolment of new patients, after achieving
high coverage levels. When using upper and lower estimates
of the number of people receiving antiretroviral therapy
between 2006 and 2008 in each country, the estimated
annual increase ranged from 0.98–1.0 million people per
year.Thecountry-settargetscenarioforecastslowernumbers
than the linear projection in 2009 and 2010, but greater
numbers by 2012, reaching a total of 8.4 million (6.3%
greater than the linear projection). The restricted scenario
forecaststhe lowestnumbers receiving antiretroviraltherapy,
reaching only 7.1 million by 2012 (10% less than the linear
projection).
Table 1 shows detailed results for the linear projection
approach, where the number of people receiving second-
line therapy is estimated to increase from around 190000
in 2008 to 520000 in 2012, equivalent to an increase from
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Figure 2:Numberofpeoplereceivingantiretroviraltherapyinlow-
and middle-income countries, reported on December 2008 and
projected for December 2009–December 2012, linear projection
and two scenarios (millions).
Table 1:Peoplereceivingantiretroviraltherapyinlow-andmiddle-
income countries, by type of regimen, reported for 2008 and
forecast for 2009–2012, linear projection (millions).
2007 2008 2009 2010 2011 2012
Number on ﬁrst
line (millions)
2.84 3.84 4.74 5.62 6.49 7.35
Percent 95.1% 95.2% 94.8% 94.4% 93.9% 93.4%
Number on second
line (millions)
0.15 0.19 0.26 0.34 0.42 0.52
Percent 4.9% 4.8% 5.2% 5.6% 6.1% 6.6%
Total (millions) 2.99 4.03 5.00 5.96 6.92 7.88
4.8% to 6.6%. Under the country-set target scenario, the
number of people receiving second-line therapy is estimated
to increase from about 190000 in 2008 to 530000 in 2012,
a relative increase from 4.8% to 6.4%. Under the restricted
scenario,thenumberofpeoplereceivingsecond-linetherapy
is estimated to increase from about 190000 in 2008 to
500000 in 2012, or from 4.8% to 7.1%.
3.5. Forecasting Demand for Antiretroviral Medicines. Table
2 presents the resulting forecast quantities of antiretrovi-
ral products required globally, using the linear projection
approach. The greatest variation in forecast demand is for
stavudine, which ranges from a decrease in demand of 39%
(from 2008 to 2012) with fast phase-out, to an increase
of 27% with slower phase-out. For other antiretroviral
molecules, the greatest annual increases are forecast for
tenofovir and emtricitabine; followed by efavirenz, ritonavir,
zidovudine, and lopinavir; lamivudine, atazanavir, and nevi-
rapine.AIDS Research and Treatment 5
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4. Discussion
We forecast that an estimated 7.9 million people will be
receiving antiretroviral therapy in low- and middle-income
countries by 2012, based on the linear projection model.
Taking into account the strengths and weaknesses of each
method, the results of the linear projection are being used
as the main basis for analysis and forecasting. Recent growth
has been approximately linear and may be the best approach
to extrapolate past trends over short periods of time. The
other two scenarios are included to show the range of
uncertainty around the projections (7.1–8.4 million).
An important strength of these projections is the inclu-
sion of two unique sources of data: the latest WHO annual
surveyonantiretroviraluseandacountrytarget-settingcon-
sultation on future antiretroviral therapy coverage. Although
conservative, these are still optimistic projections, since
many countries would require formidable implementation
eﬀorts and additional funding to scale up treatment services
at the pace observed in the recent past and to continue
enrolling an estimated 83,000 new people on ART per
month. However, treatment demand and the supply of
funding to purchase treatment were found diﬃcult to
separate. Demand for ART in low-resource countries where
donors provide the majority of ART funding may be more
subject to the availability of funding from donor agencies
than domestic constraints.
The projected estimates under the linear model suggest
that coverage would grow by 2.9 million people in three
years,representinga60%increaseoverthenumberofpeople
receiving ART by the end of 2012. However, this forecast
must be viewed within the context of various factors likely
to inﬂuence future demand: the global economic downturn,
the delivery capacity of poor countries with the greatest
HIV burden, and the implementation of the new WHO
guidelines.
The global ﬁnancial crisis is threatening countries’ ability
to sustain the progress made so far with respect to antiretro-
viral coverage, as well as eﬀorts to attain universal access
goals. It is therefore necessary to better understand the eﬀect
of the ﬁnancial crisis on antiretroviral demand, its possible
consequences, and what can be done to avoid negative
impact. After years of signiﬁcant increases for international
AIDS assistance provided by the G8, European Commission,
and other donor governments, funding remained essentially
ﬂat over the 2008-2009 period. Disbursements were $7.6
billion in 2009, compared to $7.7 billion in 2008. The
observed decrease in disbursements between 2008 and
2009 is diﬃcult to interpret, due to currency ﬂuctuations
and reporting cycle [9–11]. The global economic crisis is
not the only obstacle and other donor priorities, such as
global health, could likely impact the supply of aid for
ART.
Some of the countries with the fastest growth in the
number of people receiving ART are reaching high levels of
coverage and may be nearing a saturation point of what they
can deliver with their existing health care infrastructure. In
some other cases, a saturation point may also be reached
while high coverage remains to be attained. Growth in ART
coverage in these countries can therefore be expected to
slow down in the near future. The changes in the new
WHO recommendations to initiate ART at a threshold of
CD4 count of 350cells/mm3 will lower coverage levels in
countries, especially those with very high burden of disease.
The capacity of the health system to enroll new patients and
to sustain patients on ART in the long term will also prove to
be a central challenge.
The other factor inﬂuencing demand is the standard-
ization of treatment and the application of clinical guide-
lines. The demand scenarios for antiretroviral medicines
are based on the assumption that most low- and middle-
income countries will progressively implement the new
WHO treatment recommendations. Since the introduction
of WHO ART guidelines in 2002 (and their subsequent
updates in 2003 and 2006), successive AMDS surveys have
shown an increasing rate of country compliance with WHO
guidelines. Adoption of the new guidelines involves two
key components: the duration of the transition period for
countries to fully implement the new recommendations and
the level of continued use of stavudine.
Treating the maximum possible number of new patients
has been the priority for many governments and donors,
resulting in increased demand for less expensive formula-
tions (ﬁrst-line stavudine-containing regimens procurement
price dropped to between $64 and $122) [15]. One of the
majorrecommendationsofthe2010WHOARTguidelinesis
to provide more durable, eﬃcacious, and tolerable antiretro-
viral ﬁrst-line regimens by substituting other options for
stavudine-containing regimens. Many countries have already
started to change their national guidelines or have entered a
transition period to phase out stavudine in favour of zidovu-
dine or tenofovir for people initiating ﬁrst-line antiretroviral
therapy.
A trend comparison across results from the 2006–2008
surveys for 17 countries conﬁrms a decrease in the use of
stavudine and an increase in the use of zidovudine and
tenofovir. Countries may choose a longer transition period
to phase out stavudine in order to reduce the cost burden
of scaling up the number of people initiating antiretroviral
therapy. Despite substantial reduction over the years, ﬁrst-
line regimens that include tenofovir or zidovudine cost
up to three times more than stavudine-based regimens,
and prices of second-line regimens are still high. The
annual price per patient for ﬁrst-line regimens ranges from
$136 to $243 in low-income countries, and from $116 to
$667 in lower-middle-income countries. For second-line
regimens, the annual price per patient ranges from $572
to $803 in low-income countries and from $818 to $1545
in lower-middle-income countries. In upper-middle-income
countries, annual prices of ﬁrst-line regimens range from
$161 to $1033, while second-line regimens range from $3393
to $3647 [15]. The transition period would most likely
depend on the availability of resources over the next three
years. Certain countries with large treatment volumes, such
as Kenya, Nigeria, and South Africa, will continue to be
instrumental in driving demand.
Opportunities for a faster phase-out include new pre-
qualiﬁed formulations of ﬁxed-dose combinations, possibleAIDS Research and Treatment 7
further price reductions for medicines, and available funding
for antiretroviral treatment programmes. In addition, some
countries are already seeking eﬃciency savings through
better procurement of medicines and laboratory tests, to
sustain and expand treatment programmes [16].
Giventhesefactors,whileweforecastanincreasing-linear
demand for antiretroviral medicines, its trajectory would
more likely occur within the boundaries of the country-set
targets and the restricted scenario. While the country-set
target scenario uses data provided by the countries them-
selves, it may be over-optimistic if the economic crisis results
in slower growth in international and national ﬁnancing
of antiretroviral therapy programmes. The resulting slower
growth is diﬃcult to estimate. If funding restrictions reduce
the rate of growth by 25%, as per the restricted scenario,
then 800,000 fewer people would be receiving antiretroviral
therapy by 2012.
As in any other model, our projections have some
limitations. First, the projections are based on a small
number of past observation years. Second, while the WHO
surveys are broadly representative of ART programmes
operating across low- and middle-income countries, their
general applicability requires careful consideration. This is
especially true when extrapolating information from large
country programmes that account for a high number of
patientstocountrieswithsmall-sizedprogrammesoperating
in a wide variety of conditions. Programme size and other
features of ART services that aﬀect scale-up rates require
further investigation. Future projections should address the
barriers preventing countries from rapid scale-up and the
implementation of standard guidelines.
Our results support the notion that the demand of ART
in resource-limited settings will keep increasing and that
not only will new patients be starting ART, but those in
long-term care will also be shifted to less toxic antiretroviral
drugs. Although the price of antiretroviral medicines has
been the most important factor aﬀecting their demand,
government and donors are shifting to less toxic ARVs and
bulk purchasing will eventually push prices down. It is
expected that the use of more patient-friendly ARVs will be
also associated with better retention rates and better overall
outcomes [17, 18].
In conclusion, our demand estimates are still below
the accelerated coverage required to reach universal access
in resource-limited countries. Using classical methods of
demand forecasting, we estimated the quantities of both
antiretroviral medicines and the number of clients receiving
treatment, based on historical demand. We believe this
information to be relevant for informed demand plan-
ning. These forecasts should not downplay the fact that
many people living with HIV would beneﬁt from an
accelerated scale-up of ART. This information should be
supplemented with projections using diﬀerent approaches
and based on strategic targets. These reports should be
m a d ea v a i l a b l et od o n o r sa n dg o v e r n m e n t sa sp a r to ft h e
continuing eﬀort to provide information about the resources
needed to reach universal access to HIV treatment and
care.
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